BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

973 related articles for article (PubMed ID: 27373769)

  • 1. Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-Differentiated Neuroendocrine Tumors of the Lung.
    Wolin EM
    Chest; 2017 May; 151(5):1141-1146. PubMed ID: 27373769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine Tumors of the Lung: Current Challenges and Advances in the Diagnosis and Management of Well-Differentiated Disease.
    Hendifar AE; Marchevsky AM; Tuli R
    J Thorac Oncol; 2017 Mar; 12(3):425-436. PubMed ID: 27890494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids.
    Caplin ME; Baudin E; Ferolla P; Filosso P; Garcia-Yuste M; Lim E; Oberg K; Pelosi G; Perren A; Rossi RE; Travis WD;
    Ann Oncol; 2015 Aug; 26(8):1604-20. PubMed ID: 25646366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
    Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
    Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis and management of typical and atypical lung carcinoids.
    Pusceddu S; Lo Russo G; Macerelli M; Proto C; Vitali M; Signorelli D; Ganzinelli M; Scanagatta P; Duranti L; Trama A; Buzzoni R; Pelosi G; Pastorino U; de Braud F; Garassino MC
    Crit Rev Oncol Hematol; 2016 Apr; 100():167-76. PubMed ID: 26917456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulmonary Neuroendocrine Tumors: Adjuvant and Systemic Treatments.
    Uprety D; Halfdanarson TR; Molina JR; Leventakos K
    Curr Treat Options Oncol; 2020 Aug; 21(11):86. PubMed ID: 32862320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in neuroendocrine lung tumors.
    Travis WD
    Ann Oncol; 2010 Oct; 21 Suppl 7():vii65-71. PubMed ID: 20943645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide Receptor Radionuclide Therapy for Patients With Advanced Lung Carcinoids.
    Naraev BG; Ramirez RA; Kendi AT; Halfdanarson TR
    Clin Lung Cancer; 2019 May; 20(3):e376-e392. PubMed ID: 30910575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study.
    Dasari A; Bergsland EK; Benson AB; Cai B; Huynh L; Totev T; Shea J; Duh MS; Neary MP; Dagohoy CG; Shih BE; Maurer VE; Chan J; Kulke MH
    Oncologist; 2019 Aug; 24(8):1066-1075. PubMed ID: 30610008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diagnosis and treatment of the neuroendocrine tumors of the lung].
    Gálffy G
    Magy Onkol; 2018 Jul; 62(2):113-118. PubMed ID: 30027939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Budget impact of everolimus for the treatment of progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are advanced or metastatic.
    Rose DB; Nellesen D; Neary MP; Cai B
    J Med Econ; 2017 Apr; 20(4):395-404. PubMed ID: 27981858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic management of poorly differentiated neuroendocrine lung tumors and neuroendocrine carcinomas of the digestive system].
    Pellat A; Wislez M; Svrcek M; Hammel P; Afchain P; André T
    Bull Cancer; 2016 Oct; 103(10):880-895. PubMed ID: 27507031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges in the Diagnosis and Management of Well-Differentiated Neuroendocrine Tumors of the Lung (Typical and Atypical Carcinoid): Current Status and Future Considerations.
    Wolin EM
    Oncologist; 2015 Oct; 20(10):1123-31. PubMed ID: 26306904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The molecular pathogenesis and management of bronchial carcinoids.
    Cakir M; Grossman A
    Expert Opin Ther Targets; 2011 Apr; 15(4):457-91. PubMed ID: 21275849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic therapy for pulmonary carcinoids.
    Marquez-Medina D; Popat S
    Lung Cancer; 2015 Nov; 90(2):139-47. PubMed ID: 26371699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroendocrine tumors of the stomach (gastric carcinoids) are on the rise: small tumors, small problems?
    Scherübl H; Cadiot G; Jensen RT; Rösch T; Stölzel U; Klöppel G
    Endoscopy; 2010 Aug; 42(8):664-71. PubMed ID: 20669078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pulmonary neuroendocrine tumors. The spectrum of histologic subtypes and current concept on diagnosis and treatment].
    Langfort R; Rudziński P; Burakowska B
    Pneumonol Alergol Pol; 2010; 78(1):33-46. PubMed ID: 20162517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neuroendocrine tumors: analysis of 252 cases].
    Chi YH; Jiang WC; Du F; Sun YK; Song Y; Yang L; Zhou AP; Wang JW
    Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):67-70. PubMed ID: 23648305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Advances in the Management of Typical and Atypical Lung Carcinoids.
    Prinzi N; Rossi RE; Proto C; Leuzzi G; Raimondi A; Torchio M; Milione M; Corti F; Colombo E; Prisciandaro M; Cascella T; Spreafico C; Beninato T; Coppa J; Lo Russo G; Di Bartolomeo M; de Braud F; Pusceddu S
    Clin Lung Cancer; 2021 May; 22(3):161-169. PubMed ID: 33618994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-acting somatostatin analogues in the treatment of unresectable/metastatic neuroendocrine tumors.
    Enzler T; Fojo T
    Semin Oncol; 2017 Apr; 44(2):141-156. PubMed ID: 28923213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.